Minneapolis, MN (PRWEB) August 01, 2016
David Herbert, Chair Mayo Clinic Global Business Solutions from 2011 to 2014, joins as a Sr. Advisor to the company. David also served as the Chief Administrative Officer for Mayo Medical Laboratories from 2008 to 2011. David served as Director of Business Development at Mayo Medical Laboratories from 1998 to 2008 and prior to that in leadership roles at Mayo Medical Ventures. David’s vast and pertinent experience in the development and commercialization of laboratory developed tests should prove to be a major asset to Geneticure as it builds out its pipeline of pharmacogenomics products.
“We couldn’t be more excited and honored that David chose to join our team,” said Scott Snyder, Co-Founder/CEO of Geneticure of Geneticure. “His insights from his work at Mayo Clinic are going to help us tremendously as we grow and build a new category of medicine.”
David Herbert echoes the excitement, "I really like the Geneticure team and the practical, evidence-based approach they've taken to developing a solution to better manage Hypertension.”
"Geneticure is demonstrating how personalized medicine can improve patient care with tools physicians can use now, to better dial in the right hypertension drug for each patient from amongst all the treatment options, rather than using the trial and error, one-size-fits-all approach that is the reason typical hypertension control takes 15 months, on average" Herbert added.
In addition, Geneticure has brought on Mark Byrne, founding CEO of Assurex Health a company successfully commercializing behavioral health pharmacogenomics technology licensed from Mayo Clinic and Cincinnati Children's Hospital. He led Assurex throughout its initial development, from business plan and technology in-licensing, to successful financing, product development, and first revenues. In addition to his work at Assurex, Byrne has a wealth of C-level and entrepreneurial experience as CEO/COO at several startups including CardioEnergetics, JointVue, Arteriovations, Medical Ingenuities, Epico, and ProteoSense.
“I am excited to be part of the Geneticure team helping to bring the benefits of personalized medicine to a new patient population in hypertension management. During the work leading up to the founding of Assurex, it became clear to me that use of a patient’s genetic information to guide medication management of chronic disease was an important trend in medicine with the potential to greatly improve clinical and economic outcomes.” said Byrne.
Scott Snyder, Co-Founder/CEO of Geneticure, concurred, “Mark is an incredible asset for Geneticure. His experience at Assurex will help us follow in the right footprints and set our company up for a successful run as a personalized medicine industry leader.”
The pair executives joined Geneticure in July and say they are excited to help the company grow.
Geneticure is reinventing the standard of care for large, chronic diseases by providing Clinicians new tools to personalize therapy based on the specific patient. Geneticure uses pharmacogenomics (the study of metabolic pathways and physiologic markers that dictate varying response to drug therapy among patients) to develop tests that clinicians use to help patients get better faster, and with less cost. Geneticure tests ensure each patient receives only the right medications for their unique genetics and saving unnecessary medications, visits and adverse events. Moving well beyond drug-metabolizing enzymes, the Geneticure patented tests examine the receptors, proteins, and organ systems fundamental to drug response. With a unique understanding for the integrative physiology of complex diseases and supported by strong clinical studies using their panels, Geneticure takes personalized medicine to another level not found in healthcare today.
Learn more at https://www.geneticure.com